Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib

Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.

Related Videos
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Related Content